From GlobeNewswire: 2025-06-22 09:00:00

A study presented at the American Diabetes Association’s 85th Scientific Sessions showed that patients who adhered to treatment with investigational CagriSema experienced significant and clinically meaningful weight loss. The study found that participants lost a mean of 22.7% of their body weight at 68 weeks, compared to 2.3% in the placebo group. Safety data from the REDEFINE 1 trial showed low discontinuation rates due to adverse events, with mainly gastrointestinal issues reported. Another study, REDEFINE 2, also showed promising results with CagriSema in adults with obesity and type 2 diabetes, with a greater proportion of participants achieving significant weight loss compared to placebo. Novo Nordisk is continuing to investigate the potential of CagriSema through ongoing clinical trials.



Read more at GlobeNewswire: CagriSema 2.4 mg / 2.4 mg demonstrated